BioDelivery Sciences' Prochlorperazine Oral Buccal Tablet Is Bucked Off Course
This article was originally published in The Pink Sheet Daily
FDA "not approvable" letter for Emezine is due to the pharmacokinetic profile of its oral buccal tablet formulation.
You may also be interested in...
The company believes that the studies of the anti-emetic will take six to nine months to complete.
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.